119-S-3758 Journalist Public Summary

Headline Summary

Make overdose‑reversal medications like naloxone free and available without a prescription at VA pharmacies for eligible veterans and their caregivers, with privacy safeguards and VA reporting requirements.

What It Does

The bill directs the Department of Veterans Affairs to offer opioid overdose rescue medications (for example, naloxone) at VA pharmacies to any “covered veteran” and their VA‑recognized caregiver at no cost and without a prescription. It requires the VA to provide simple drug‑use instructions, limits any personally identifiable information to health‑care quality purposes only, and bars using that information to block employment or as evidence of drug use. It also requires the VA to report back to Congress within two years (and annually after) and to assess whether to expand access to immediate family members and to non‑VA providers who treat veterans. (congress.gov)

Why It Matters

In an overdose emergency, seconds count. Letting veterans and caregivers walk into a VA pharmacy and get naloxone without red tape could make it easier to prevent deaths, while the privacy rules aim to reduce fears that asking for help could be used against them.

Who’s For It

• Lead sponsors: Sens. Jeanne Shaheen (D‑NH) and Mike Crapo (R‑ID) say the bill removes barriers to life‑saving overdose‑reversal treatments for veterans. (shaheen.senate.gov)
• Bipartisan signal: Congress.gov lists Shaheen as sponsor and Crapo as cosponsor. (congress.gov)

Who’s Against It

• No formal opposition has been publicly noted in official trackers as of March 19, 2026.
• Potential concerns some may raise: how well privacy protections are enforced; that eligibility is limited to “covered” veterans and VA‑recognized caregivers (not all family members); and whether VA pharmacies and staff have the resources for outreach and training.

What’s Next

As of March 19, 2026, Congress.gov shows the bill in the Senate Veterans’ Affairs Committee following its February 2 introduction. If the committee reports it, the next step would be consideration by the full Senate; if passed, it would move to the House. (congress.gov)